Literature DB >> 7579459

Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose.

M Lapela1, S Leskinen, H R Minn, P Lindholm, P J Klemi, K O Söderström, J Bergman, M Haaparanta, U Ruotsalainen, O Solin, H Joensuu.   

Abstract

Glucose metabolism has been shown to be increased in neoplastic tissue. It has been suggested that high activity of glucose metabolism is associated with a high grade of malignancy of human cancer. We studied in vivo glucose metabolism in 22 patients with untreated non-Hodgkin's lymphoma with fluorine-18-fluorodeoxyglucose (FDG) and positron emission tomography (PET). FDG uptake in lymphoma deposits was measured blinded to clinical data, and compared with histologic classification and proliferative activity. Tracer uptake was measured by using two indices of FDG accumulation: the standardized uptake value (SUV) and the regional metabolic rate (rMR) for the tracer. The median SUV of the lymphomas was 8.5 (range, 3.5 to 31.0), and the median rMR 22.7 mumol/100 g/min (range, 9.0 to 124.3 mumol/100 g/min). A high FDG uptake in tumors was associated with high histologic degree of malignancy as defined by the Working Formulation (P = .005 for the SUV, and P = .04 for the rMR) or by the Kiel classification (P = .003 for the SUV, and P = .02 for the rMR). A high FDG accumulation was also associated with a high S-phase fraction (r = .786 for the SUV, P = .0002; and r = .774 for the rMR, P = .02). We conclude that in untreated non-Hodgkin's lymphomas high FDG uptake is associated with high histologic grade of malignancy and a high proliferation rate. This minimally invasive method may find application in assessing lymphoma lesions in patients who are poor candidates for surgery, and it may provide further information in cases where the grade of aggressiveness of lymphoma is not settled based on clinical or histologic data.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579459

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  PET in lymphoma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

Review 2.  FDG PET-CT in follicular lymphoma: a case-based evidence review.

Authors:  Stephen D Smith; Mary Redman; Kieron Dunleavy
Journal:  Blood       Date:  2014-12-19       Impact factor: 22.113

3.  Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma.

Authors:  Hossein Ahmadzadehfar; Margarida Rodrigues; Rasoul Zakavi; Peter Knoll; Siroos Mirzaei
Journal:  Med Oncol       Date:  2010-06-04       Impact factor: 3.064

4.  Effectiveness of positron emission tomography for the detection of melanoma metastases.

Authors:  W D Holder; R L White; J H Zuger; E J Easton; F L Greene
Journal:  Ann Surg       Date:  1998-05       Impact factor: 12.969

Review 5.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

Review 6.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

7.  The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder.

Authors:  Daan Dierickx; Thomas Tousseyn; Annelies Requilé; Raf Verscuren; Xavier Sagaert; Julie Morscio; Iwona Wlodarska; An Herreman; Dirk Kuypers; Johan Van Cleemput; Frederik Nevens; Lieven Dupont; Anne Uyttebroeck; Jacques Pirenne; Christiane De Wolf-Peeters; Gregor Verhoef; Lieselot Brepoels; Olivier Gheysens
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

8.  Prognostic Value of Metabolic Tumor Volume Estimated by (18) F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease.

Authors:  Jihyun Kim; Junshik Hong; Seog Gyun Kim; Kyung Hoon Hwang; Minsu Kim; Hee Kyung Ahn; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-05-29

Review 9.  Limitations of PET for imaging lymphoma.

Authors:  Sally F Barrington; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-13       Impact factor: 9.236

Review 10.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.